L-Lysine — Research Profile

Clinical evidence suggests it can. A 1987 RCT found 1 g lysine three times daily significantly reduced herpes simplex recurrence and severity ^[1]. The mechanism is competitive inhibition of arginine, an amino acid HSV needs to replicate. For prevention, 500-1000 mg daily is commonly used; during active outbreaks, 3 g/day is typical. Results vary between individuals.

They have opposing effects regarding herpes — lysine inhibits HSV replication while arginine may promote it. If taking lysine for cold sore prevention, avoid high-dose arginine supplementation. For general health, moderate amounts of both from food are fine. If using both as supplements, take them at different times of day.

For general health, 500-1000 mg daily is sufficient. For herpes prevention, 1-3 g daily is the studied range. During active cold sore outbreaks, up to 3 g daily in divided doses has been used. The RDA for lysine is about 38 mg/kg body weight, easily met through a diet containing adequate animal protein.

Oral L-lysine monohydrochloride is the form with direct trial support, including the placebo-controlled cold-sore study. Free-base L-lysine and the HCl salt deliver the same amino acid, differing mainly in that the salt form is the standard tablet material; topical lysine creams exist but the outbreak-reduction evidence is for oral dosing. There is no good evidence that any specialized form outperforms plain oral L-lysine.

The most direct human evidence is for recurrent herpes simplex (cold sores): a double-blind trial found 3 g/day cut outbreak frequency by an average of 2.4 infections and reduced symptom severity and healing time. A separate trial of lysine combined with arginine reduced anxiety, with lower basal cortisol in men. Claims for bone health, wound healing, and athletic performance are not backed by comparable controlled data for lysine on its own.

In the cold-sore trial the effective regimen was 1 g taken three times daily, for a total of 3 g/day. The anxiety study used 2.64 g/day paired with arginine. Whatever the goal, staying below the 6 g/day no-observed-adverse-effect threshold keeps intake within the range covered by safety reviews.

No study has directly compared times of day, so an optimal clock time is not established. The cold-sore trial simply split the dose into three portions across the day, which is a practical way to keep blood levels steady rather than a proven timing advantage. For cold-sore prevention specifically, separating lysine from arginine-rich foods is a reasonable theoretical practice given the two amino acids compete.

Across the human safety literature, the adverse effects reported were mainly gastrointestinal, including nausea, stomach ache, and diarrhea, and were concentrated at higher doses. When results were pooled, these symptoms were not significantly more common than with placebo (risk ratio 1.02, 95% CI 0.96-1.07). Serious adverse effects were not a feature of the reviewed trials.

Consumer drug-reference monographs report no known serious drug interactions for lysine, though it has not been the subject of dedicated human interaction trials. The one documented pharmacologic point is that lysine can increase how much calcium the body absorbs, so taking it alongside calcium supplements can raise calcium levels; kidney disease is also listed as a caution. Overall the human interaction evidence is thin, and specific drug pairings have not been well characterized.

The group with the clearest evidence is people who get frequent recurrent cold sores, where 3 g/day reduced outbreak frequency and severity. Most people already meet their lysine needs from protein-rich foods such as meat, fish, dairy, and legumes, so routine supplementation offers little to the general population; those on grain-heavy or low-legume vegan diets are the most likely to have lower dietary intake. It is a targeted supplement rather than a broadly recommended daily one.

L-Lysine is not an acute-onset supplement, and no trial has pinned down a precise time to effect. For recurrent cold sores, the main placebo-controlled trial dosed 1 g three times daily and measured a reduction in outbreak frequency over 6 months of continuous use, so it works as ongoing prophylaxis rather than a same-day fix. In the one anxiety trial, effects on trait anxiety and cortisol were assessed after a full week of daily lysine plus arginine.

Two systematic reviews of human oral-lysine studies found it well tolerated, identifying a provisional no-observed-adverse-effect level of 6 g/day, with subjective gastrointestinal complaints as the only notable adverse effect. Across the trials they pooled, dosing periods extended up to about three years (1,095 days). Robust safety data at doses above 6 g/day, and for truly indefinite daily use, remain limited.

Yes. Systematic-review analysis set a provisional no-observed-adverse-effect level of 6 g/day, above which gastrointestinal effects such as nausea, stomach ache, and diarrhea become more likely; no formal tolerable upper intake level has been established. At the doses actually studied, pooled analysis found gastrointestinal symptoms were not significantly higher than with placebo (risk ratio 1.02).

The best-studied pairing is lysine with arginine: a trial gave 2.64 g of each daily and saw reduced anxiety, and cortisol reduction in men. Note a caveat specific to cold-sore use, however: lysine and arginine compete for the same transport, and arginine can promote herpes simplex replication, so loading up on arginine may work against lysine's antiviral rationale. There is no evidence that stacking lysine with unrelated supplements improves its effects.

Choose the L-lysine isomer (the biologically usable form), typically sold as L-lysine monohydrochloride, which is the exact form used in the clinical trials. Because lysine is a single amino acid rather than a plant extract, there is no active-compound percentage to standardize; the meaningful checks are that the label states the L-lysine base dose and that the product carries third-party purity testing. Match the labeled amount to a studied dose rather than assuming more is better.